Ketcham John M, Marshall Lisa A, Talay Oezcan
FLX Bio, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States.
ACS Med Chem Lett. 2018 Sep 10;9(10):953-955. doi: 10.1021/acsmedchemlett.8b00351. eCollection 2018 Oct 11.
Recruitment of naturally occurring suppressive CD4, CD25, and FOXP3 regulatory T cells (T) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human T express CCR4 and can be recruited to the TME through the C-C chemokines CCL17 and CCL22. We have recently developed a series of potent, orally bioavailable small molecule antagonists of CCR4 that can block recruitment of T into the TME.
将天然存在的具有抑制作用的CD4、CD25和FOXP3调节性T细胞（T细胞）募集到肿瘤微环境（TME）中，可能会削弱接受免疫肿瘤学（IO）药物治疗患者的抗肿瘤反应。人T细胞表达CCR4，并可通过C-C趋化因子CCL17和CCL22被募集到TME中。我们最近开发了一系列强效的、口服生物可利用的CCR4小分子拮抗剂，它们可以阻止T细胞募集到TME中。
